Jeffrey S Gerber1,2,3, Rachael K Ross1, Matthew Bryan3, A Russell Localio3, Julia E Szymczak3, Richard Wasserman4, Darlene Barkman5, Folasade Odeniyi1, Kathryn Conaboy5, Louis Bell1,6, Theoklis E Zaoutis1,2,3, Alexander G Fiks1,3,6. 1. Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 2. Division of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 3. Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia. 4. Larner College of Medicine, University of Vermont, Burlington. 5. Division of Patient and Family Experience, Family and Patient Services Department, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 6. Division of General Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Abstract
Importance: Acute respiratory tract infections account for the majority of antibiotic exposure in children, and broad-spectrum antibiotic prescribing for acute respiratory tract infections is increasing. It is not clear whether broad-spectrum treatment is associated with improved outcomes compared with narrow-spectrum treatment. Objective: To compare the effectiveness of broad-spectrum and narrow-spectrum antibiotic treatment for acute respiratory tract infections in children. Design, Setting, and Participants: A retrospective cohort study assessing clinical outcomes and a prospective cohort study assessing patient-centered outcomes of children between the ages of 6 months and 12 years diagnosed with an acute respiratory tract infection and prescribed an oral antibiotic between January 2015 and April 2016 in a network of 31 pediatric primary care practices in Pennsylvania and New Jersey. Stratified and propensity score-matched analyses to account for confounding by clinician and by patient-level characteristics, respectively, were implemented for both cohorts. Exposures: Broad-spectrum antibiotics vs narrow-spectrum antibiotics. Main Outcomes and Measures: In the retrospective cohort, the primary outcomes were treatment failure and adverse events 14 days after diagnosis. In the prospective cohort, the primary outcomes were quality of life, other patient-centered outcomes, and patient-reported adverse events. Results: Of 30 159 children in the retrospective cohort (19 179 with acute otitis media; 6746, group A streptococcal pharyngitis; and 4234, acute sinusitis), 4307 (14%) were prescribed broad-spectrum antibiotics including amoxicillin-clavulanate, cephalosporins, and macrolides. Broad-spectrum treatment was not associated with a lower rate of treatment failure (3.4% for broad-spectrum antibiotics vs 3.1% for narrow-spectrum antibiotics; risk difference for full matched analysis, 0.3% [95% CI, -0.4% to 0.9%]). Of 2472 children enrolled in the prospective cohort (1100 with acute otitis media; 705, group A streptococcal pharyngitis; and 667, acute sinusitis), 868 (35%) were prescribed broad-spectrum antibiotics. Broad-spectrum antibiotics were associated with a slightly worse child quality of life (score of 90.2 for broad-spectrum antibiotics vs 91.5 for narrow-spectrum antibiotics; score difference for full matched analysis, -1.4% [95% CI, -2.4% to -0.4%]) but not with other patient-centered outcomes. Broad-spectrum treatment was associated with a higher risk of adverse events documented by the clinician (3.7% for broad-spectrum antibiotics vs 2.7% for narrow-spectrum antibiotics; risk difference for full matched analysis, 1.1% [95% CI, 0.4% to 1.8%]) and reported by the patient (35.6% for broad-spectrum antibiotics vs 25.1% for narrow-spectrum antibiotics; risk difference for full matched analysis, 12.2% [95% CI, 7.3% to 17.2%]). Conclusions and Relevance: Among children with acute respiratory tract infections, broad-spectrum antibiotics were not associated with better clinical or patient-centered outcomes compared with narrow-spectrum antibiotics, and were associated with higher rates of adverse events. These data support the use of narrow-spectrum antibiotics for most children with acute respiratory tract infections.
Importance: Acute respiratory tract infections account for the majority of antibiotic exposure in children, and broad-spectrum antibiotic prescribing for acute respiratory tract infections is increasing. It is not clear whether broad-spectrum treatment is associated with improved outcomes compared with narrow-spectrum treatment. Objective: To compare the effectiveness of broad-spectrum and narrow-spectrum antibiotic treatment for acute respiratory tract infections in children. Design, Setting, and Participants: A retrospective cohort study assessing clinical outcomes and a prospective cohort study assessing patient-centered outcomes of children between the ages of 6 months and 12 years diagnosed with an acute respiratory tract infection and prescribed an oral antibiotic between January 2015 and April 2016 in a network of 31 pediatric primary care practices in Pennsylvania and New Jersey. Stratified and propensity score-matched analyses to account for confounding by clinician and by patient-level characteristics, respectively, were implemented for both cohorts. Exposures: Broad-spectrum antibiotics vs narrow-spectrum antibiotics. Main Outcomes and Measures: In the retrospective cohort, the primary outcomes were treatment failure and adverse events 14 days after diagnosis. In the prospective cohort, the primary outcomes were quality of life, other patient-centered outcomes, and patient-reported adverse events. Results: Of 30 159 children in the retrospective cohort (19 179 with acute otitis media; 6746, group A streptococcal pharyngitis; and 4234, acute sinusitis), 4307 (14%) were prescribed broad-spectrum antibiotics including amoxicillin-clavulanate, cephalosporins, and macrolides. Broad-spectrum treatment was not associated with a lower rate of treatment failure (3.4% for broad-spectrum antibiotics vs 3.1% for narrow-spectrum antibiotics; risk difference for full matched analysis, 0.3% [95% CI, -0.4% to 0.9%]). Of 2472 children enrolled in the prospective cohort (1100 with acute otitis media; 705, group A streptococcal pharyngitis; and 667, acute sinusitis), 868 (35%) were prescribed broad-spectrum antibiotics. Broad-spectrum antibiotics were associated with a slightly worse child quality of life (score of 90.2 for broad-spectrum antibiotics vs 91.5 for narrow-spectrum antibiotics; score difference for full matched analysis, -1.4% [95% CI, -2.4% to -0.4%]) but not with other patient-centered outcomes. Broad-spectrum treatment was associated with a higher risk of adverse events documented by the clinician (3.7% for broad-spectrum antibiotics vs 2.7% for narrow-spectrum antibiotics; risk difference for full matched analysis, 1.1% [95% CI, 0.4% to 1.8%]) and reported by the patient (35.6% for broad-spectrum antibiotics vs 25.1% for narrow-spectrum antibiotics; risk difference for full matched analysis, 12.2% [95% CI, 7.3% to 17.2%]). Conclusions and Relevance: Among children with acute respiratory tract infections, broad-spectrum antibiotics were not associated with better clinical or patient-centered outcomes compared with narrow-spectrum antibiotics, and were associated with higher rates of adverse events. These data support the use of narrow-spectrum antibiotics for most children with acute respiratory tract infections.
Authors: Anthony W Chow; Michael S Benninger; Itzhak Brook; Jan L Brozek; Ellie J C Goldstein; Lauri A Hicks; George A Pankey; Mitchel Seleznick; Gregory Volturo; Ellen R Wald; Thomas M File Journal: Clin Infect Dis Date: 2012-03-20 Impact factor: 9.079
Authors: Nadine Shehab; Maribeth C Lovegrove; Andrew I Geller; Kathleen O Rose; Nina J Weidle; Daniel S Budnitz Journal: JAMA Date: 2016-11-22 Impact factor: 56.272
Authors: Stanford T Shulman; Alan L Bisno; Herbert W Clegg; Michael A Gerber; Edward L Kaplan; Grace Lee; Judith M Martin; Chris Van Beneden Journal: Clin Infect Dis Date: 2012-11-15 Impact factor: 9.079
Authors: James W Varni; Christine A Limbers; Katie Neighbors; Kris Schulz; Judith E C Lieu; Robert W Heffer; Krista Tuzinkiewicz; Rita Mangione-Smith; Jerry J Zimmerman; Estella M Alonso Journal: Qual Life Res Date: 2010-08-22 Impact factor: 3.440
Authors: Julia E Szymczak; Sarah B Klieger; Matthew Miller; Alexander G Fiks; Jeffrey S Gerber Journal: J Pediatric Infect Dis Soc Date: 2018-12-03 Impact factor: 3.164
Authors: Laura M King; Monina Bartoces; Katherine E Fleming-Dutra; Rebecca M Roberts; Lauri A Hicks Journal: Clin Infect Dis Date: 2020-01-16 Impact factor: 9.079
Authors: Maribeth C Lovegrove; Andrew I Geller; Katherine E Fleming-Dutra; Nadine Shehab; Mathew R P Sapiano; Daniel S Budnitz Journal: J Pediatric Infect Dis Soc Date: 2019-11-06 Impact factor: 3.164
Authors: Yasmeen Abouelhassan; Aaron T Garrison; Hongfen Yang; Alejandra Chávez-Riveros; Gena M Burch; Robert W Huigens Journal: J Med Chem Date: 2019-04-18 Impact factor: 7.446
Authors: Matthew J Lipshaw; Michelle Eckerle; Todd A Florin; Eric J Crotty; Jessi Lipscomb; Judd Jacobs; Mantosh S Rattan; Richard M Ruddy; Samir S Shah; Lilliam Ambroggio Journal: Pediatrics Date: 2020-03-16 Impact factor: 7.124
Authors: Susan C Lipsett; Matthew Hall; Lilliam Ambroggio; Adam L Hersh; Samir S Shah; Thomas V Brogan; Jeffrey S Gerber; Derek J Williams; Carlos G Grijalva; Anne J Blaschke; Mark I Neuman Journal: J Pediatr Date: 2020-10-10 Impact factor: 4.406
Authors: Holly M Frost; Lauren F Becker; Bryan C Knepper; Katherine C Shihadeh; Timothy C Jenkins Journal: J Pediatr Date: 2020-02-25 Impact factor: 4.406
Authors: Rebecca G Same; Alice J Hsu; Sara E Cosgrove; Eili Y Klein; Joe Amoah; Adam L Hersh; Matthew P Kronman; Pranita D Tamma Journal: J Pediatric Infect Dis Soc Date: 2021-05-28 Impact factor: 3.164
Authors: Kristen A Eller; Thomas R Aunins; Colleen M Courtney; Jocelyn K Campos; Peter B Otoupal; Keesha E Erickson; Nancy E Madinger; Anushree Chatterjee Journal: Commun Biol Date: 2021-03-12